Novo Nordisk’s Pipeline Progress Collides With a Darkening Revenue Outlook

Novo Nordisk balances rare-disease wins and obesity pipeline data against a grim 2026 revenue forecast and rising competition from generics and oral GLP-1 drugs.

The Danish pharmaceutical giant finds itself in an unusual tug-of-war. On one side, clinical advances in both rare diseases and obesity are generating headlines. On the other, a deteriorating financial forecast and fresh competitive threats are weighing heavily on sentiment. With two major catalysts approaching — a medical conference in Istanbul and first-quarter results due next week — investors are bracing for clarity.

A Rare-Disease Breakthrough That’s Flying Under the Radar

Novo Nordisk has quietly scored a significant win in hemophilia. Phase 3 data for denecimig, a monthly treatment for Hemophilia A, showed a 99% reduction in bleeding episodes. That compares favorably even to existing prophylactic therapies, where the drug cut bleeding rates by 43%. A US approval application was already filed last September.

The company is also making headway in other rare blood disorders. Etavopivat, a candidate targeting sickle cell disease, reduced vaso-occlusive crises by 27% in a Phase 3 trial, with a regulatory submission planned for the second half of 2026.

These developments come as the broader industry pivots toward orphan drugs. Just this week, the Chiesi Group acquired KalVista for $1.9 billion, underscoring the growing appetite for niche therapies. Novo Nordisk’s positioning in this space is strengthening, even if the market has yet to reward it.

Istanbul Takes Center Stage for Obesity Pipeline

Later this month, the European Congress on Obesity (ECO) in Istanbul will serve as a showcase for the company’s metabolic pipeline. Novo Nordisk plans to present 52 studies, headlined by data on a high-dose Wegovy variant containing 7.2 milligrams of semaglutide. This formulation is designed for patients whose weight loss stalls on standard doses.

Also in the spotlight is CagriSema, a combination of semaglutide and a long-acting amylin analogue aimed at more potent appetite suppression. A separate study will examine semaglutide’s cardiovascular effects specifically in menopausal women — a demographic often overlooked in metabolic research.

Competitive Pressure Intensifies on Multiple Fronts

While the pipeline narrative is compelling, the core business is facing headwinds from several directions. Canada has become the first G7 country to approve a generic version of semaglutide, manufactured by Dr. Reddy’s Laboratories. That marks a direct challenge to Ozempic’s pricing power in a key market.

In the US, the FDA recently cleared a new daily oral weight-loss pill from a major competitor, adding to the list of alternatives encroaching on Novo Nordisk’s turf. However, early prescription data for Eli Lilly’s new oral GLP-1 drug Foundayo suggests a sluggish launch, which has provided some short-term relief to Novo Nordisk’s share price.

Financial Outlook Remains Grim

Despite these pockets of optimism, the company’s own guidance paints a sobering picture. Management expects revenue to decline between 5% and 13% in 2026, citing pricing pressure from Medicare and hefty restructuring costs. Kepler Capital analysts have maintained a “Hold” rating, pointing to the same headwinds.

The stock has recovered somewhat from recent lows, climbing nearly 11% over the past month to €35.17. But the year-to-date loss still stands at roughly 21%, and on a 12-month basis the decline exceeds 41%. A relative strength index of 24.9 suggests the shares are deeply oversold.

Buybacks and Q1 Results Offer a Litmus Test

A share repurchase program is providing a floor under the stock. A tranche worth nearly 4 billion Danish kroner is running until early May, part of a broader plan to buy back up to 15 billion kroner over the course of a year.

The next major inflection point comes on May 6, when Novo Nordisk reports first-quarter earnings. Analysts are forecasting earnings per share of $0.87. More importantly, the report will offer the first concrete evidence of how deeply pricing pressure is cutting into margins under the new, downbeat annual guidance. Investors will be watching closely to see whether the pipeline’s promise can outweigh the core business’s pain.